JP2017524662A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524662A5 JP2017524662A5 JP2016572445A JP2016572445A JP2017524662A5 JP 2017524662 A5 JP2017524662 A5 JP 2017524662A5 JP 2016572445 A JP2016572445 A JP 2016572445A JP 2016572445 A JP2016572445 A JP 2016572445A JP 2017524662 A5 JP2017524662 A5 JP 2017524662A5
- Authority
- JP
- Japan
- Prior art keywords
- retention structure
- gastric retention
- structure according
- configuration
- drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014759 maintenance of location Effects 0.000 claims description 122
- 229920000642 polymer Polymers 0.000 claims description 120
- 230000002496 gastric effect Effects 0.000 claims description 88
- 239000013543 active substance Substances 0.000 claims description 40
- -1 polysiloxane Polymers 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 18
- 239000002775 capsule Substances 0.000 claims description 9
- 229920001610 polycaprolactone Polymers 0.000 claims description 9
- 239000004632 polycaprolactone Substances 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 claims description 7
- 239000000935 antidepressant agent Substances 0.000 claims description 7
- 229940005513 antidepressants Drugs 0.000 claims description 7
- 229940088597 hormone Drugs 0.000 claims description 7
- 239000005556 hormone Substances 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 210000002784 stomach Anatomy 0.000 claims description 6
- 230000000717 retained effect Effects 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- 229920001054 Poly(ethylene‐co‐vinyl acetate) Polymers 0.000 claims description 4
- 239000004952 Polyamide Substances 0.000 claims description 4
- 229920002732 Polyanhydride Polymers 0.000 claims description 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 229930003316 Vitamin D Natural products 0.000 claims description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 4
- 239000003430 antimalarial agent Substances 0.000 claims description 4
- 239000000164 antipsychotic agent Substances 0.000 claims description 4
- 229960001948 caffeine Drugs 0.000 claims description 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 229960005069 calcium Drugs 0.000 claims description 4
- 229940039227 diagnostic agent Drugs 0.000 claims description 4
- 239000000032 diagnostic agent Substances 0.000 claims description 4
- 229960000304 folic acid Drugs 0.000 claims description 4
- 235000019152 folic acid Nutrition 0.000 claims description 4
- 239000011724 folic acid Substances 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 229960003284 iron Drugs 0.000 claims description 4
- 229950008325 levothyroxine Drugs 0.000 claims description 4
- 229960003512 nicotinic acid Drugs 0.000 claims description 4
- 235000001968 nicotinic acid Nutrition 0.000 claims description 4
- 239000011664 nicotinic acid Substances 0.000 claims description 4
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 4
- 229920000058 polyacrylate Polymers 0.000 claims description 4
- 229920002647 polyamide Polymers 0.000 claims description 4
- 229920000728 polyester Polymers 0.000 claims description 4
- 229920001296 polysiloxane Polymers 0.000 claims description 4
- 229920002635 polyurethane Polymers 0.000 claims description 4
- 239000004814 polyurethane Substances 0.000 claims description 4
- 235000019157 thiamine Nutrition 0.000 claims description 4
- 229960003495 thiamine Drugs 0.000 claims description 4
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 4
- 239000011721 thiamine Substances 0.000 claims description 4
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- 235000019166 vitamin D Nutrition 0.000 claims description 4
- 239000011710 vitamin D Substances 0.000 claims description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 4
- 229940046008 vitamin d Drugs 0.000 claims description 4
- 235000016804 zinc Nutrition 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 238000005452 bending Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 18
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 9
- 239000003146 anticoagulant agent Substances 0.000 claims 9
- 229940127219 anticoagulant drug Drugs 0.000 claims 9
- 235000015872 dietary supplement Nutrition 0.000 claims 9
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 6
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 6
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 6
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 claims 6
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims 6
- 229940123934 Reductase inhibitor Drugs 0.000 claims 6
- 239000002160 alpha blocker Substances 0.000 claims 6
- 230000000202 analgesic effect Effects 0.000 claims 6
- 230000001430 anti-depressive effect Effects 0.000 claims 6
- 230000000561 anti-psychotic effect Effects 0.000 claims 6
- 239000003443 antiviral agent Substances 0.000 claims 6
- 239000002249 anxiolytic agent Substances 0.000 claims 6
- 230000000949 anxiolytic effect Effects 0.000 claims 6
- 229960004372 aripiprazole Drugs 0.000 claims 6
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 claims 6
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 6
- 229960001736 buprenorphine Drugs 0.000 claims 6
- 229940097217 cardiac glycoside Drugs 0.000 claims 6
- 239000002368 cardiac glycoside Substances 0.000 claims 6
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 6
- 229960003722 doxycycline Drugs 0.000 claims 6
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims 6
- 230000000147 hypnotic effect Effects 0.000 claims 6
- 229960003444 immunosuppressant agent Drugs 0.000 claims 6
- 230000001861 immunosuppressant effect Effects 0.000 claims 6
- 239000003018 immunosuppressive agent Substances 0.000 claims 6
- 229960004640 memantine Drugs 0.000 claims 6
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 6
- 229960001797 methadone Drugs 0.000 claims 6
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims 6
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 6
- 229960001534 risperidone Drugs 0.000 claims 6
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 6
- 229960000672 rosuvastatin Drugs 0.000 claims 6
- 239000000932 sedative agent Substances 0.000 claims 6
- 230000001624 sedative effect Effects 0.000 claims 6
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 6
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 6
- 229930002534 steroid glycoside Natural products 0.000 claims 6
- 201000009032 substance abuse Diseases 0.000 claims 6
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 claims 3
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims 3
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 claims 3
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims 3
- 239000005465 B01AC22 - Prasugrel Substances 0.000 claims 3
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 3
- 235000001258 Cinchona calisaya Nutrition 0.000 claims 3
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 claims 3
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims 3
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 3
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims 3
- 239000004721 Polyphenylene oxide Substances 0.000 claims 3
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 claims 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 3
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 claims 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 3
- 239000004012 Tofacitinib Substances 0.000 claims 3
- 229960001444 amodiaquine Drugs 0.000 claims 3
- 230000003444 anaesthetic effect Effects 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 230000001760 anti-analgesic effect Effects 0.000 claims 3
- 230000001088 anti-asthma Effects 0.000 claims 3
- 230000000843 anti-fungal effect Effects 0.000 claims 3
- 230000001387 anti-histamine Effects 0.000 claims 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims 3
- 230000002460 anti-migrenic effect Effects 0.000 claims 3
- 230000001022 anti-muscarinic effect Effects 0.000 claims 3
- 230000001028 anti-proliverative effect Effects 0.000 claims 3
- 230000001754 anti-pyretic effect Effects 0.000 claims 3
- 239000000924 antiasthmatic agent Substances 0.000 claims 3
- 229940124350 antibacterial drug Drugs 0.000 claims 3
- 239000001961 anticonvulsive agent Substances 0.000 claims 3
- 229940121375 antifungal agent Drugs 0.000 claims 3
- 239000000739 antihistaminic agent Substances 0.000 claims 3
- 229940124433 antimigraine drug Drugs 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229940041181 antineoplastic drug Drugs 0.000 claims 3
- 239000003096 antiparasitic agent Substances 0.000 claims 3
- 239000002221 antipyretic Substances 0.000 claims 3
- 229960004191 artemisinin Drugs 0.000 claims 3
- 229930101531 artemisinin Natural products 0.000 claims 3
- 229960002521 artenimol Drugs 0.000 claims 3
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 claims 3
- 229960004991 artesunate Drugs 0.000 claims 3
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 claims 3
- KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 claims 3
- 229960003159 atovaquone Drugs 0.000 claims 3
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 3
- 229960004099 azithromycin Drugs 0.000 claims 3
- 230000003385 bacteriostatic effect Effects 0.000 claims 3
- 230000003115 biocidal effect Effects 0.000 claims 3
- 229920001222 biopolymer Polymers 0.000 claims 3
- 229940124630 bronchodilator Drugs 0.000 claims 3
- 239000002327 cardiovascular agent Substances 0.000 claims 3
- 229940125692 cardiovascular agent Drugs 0.000 claims 3
- 229960001803 cetirizine Drugs 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229960003677 chloroquine Drugs 0.000 claims 3
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims 3
- 229960002227 clindamycin Drugs 0.000 claims 3
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims 3
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims 3
- 229960003009 clopidogrel Drugs 0.000 claims 3
- 229960001338 colchicine Drugs 0.000 claims 3
- 239000003246 corticosteroid Substances 0.000 claims 3
- 229960003834 dapagliflozin Drugs 0.000 claims 3
- 229960000860 dapsone Drugs 0.000 claims 3
- 229960005156 digoxin Drugs 0.000 claims 3
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims 3
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims 3
- 229930016266 dihydroartemisinin Natural products 0.000 claims 3
- 229960003530 donepezil Drugs 0.000 claims 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims 3
- 230000005489 elastic deformation Effects 0.000 claims 3
- 239000003792 electrolyte Substances 0.000 claims 3
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims 3
- 229960004341 escitalopram Drugs 0.000 claims 3
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims 3
- 229960000815 ezetimibe Drugs 0.000 claims 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 3
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims 3
- 229960003088 loratadine Drugs 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 229960001962 mefloquine Drugs 0.000 claims 3
- 229960001929 meloxicam Drugs 0.000 claims 3
- 239000002207 metabolite Substances 0.000 claims 3
- 239000011707 mineral Substances 0.000 claims 3
- 235000010755 mineral Nutrition 0.000 claims 3
- 229960005127 montelukast Drugs 0.000 claims 3
- 239000003158 myorelaxant agent Substances 0.000 claims 3
- 229960004127 naloxone Drugs 0.000 claims 3
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 3
- 239000004090 neuroprotective agent Substances 0.000 claims 3
- 230000000324 neuroprotective effect Effects 0.000 claims 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 3
- 229960005017 olanzapine Drugs 0.000 claims 3
- 230000001499 parasympathomimetic effect Effects 0.000 claims 3
- 239000000419 plant extract Substances 0.000 claims 3
- 229920000570 polyether Polymers 0.000 claims 3
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 claims 3
- 229960004197 prasugrel Drugs 0.000 claims 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 3
- 229960004618 prednisone Drugs 0.000 claims 3
- 229960005179 primaquine Drugs 0.000 claims 3
- INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 claims 3
- 229960005385 proguanil Drugs 0.000 claims 3
- 150000003180 prostaglandins Chemical class 0.000 claims 3
- 239000000612 proton pump inhibitor Substances 0.000 claims 3
- 229940126409 proton pump inhibitor Drugs 0.000 claims 3
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 claims 3
- 229960000611 pyrimethamine Drugs 0.000 claims 3
- 229960000948 quinine Drugs 0.000 claims 3
- 150000003431 steroids Chemical class 0.000 claims 3
- 231100000736 substance abuse Toxicity 0.000 claims 3
- 208000011117 substance-related disease Diseases 0.000 claims 3
- 229960004673 sulfadoxine Drugs 0.000 claims 3
- VLYWMPOKSSWJAL-UHFFFAOYSA-N sulfamethoxypyridazine Chemical compound N1=NC(OC)=CC=C1NS(=O)(=O)C1=CC=C(N)C=C1 VLYWMPOKSSWJAL-UHFFFAOYSA-N 0.000 claims 3
- 229960004936 sulfamethoxypyridazine Drugs 0.000 claims 3
- 229940124530 sulfonamide Drugs 0.000 claims 3
- 150000003456 sulfonamides Chemical class 0.000 claims 3
- 229940099268 synthroid Drugs 0.000 claims 3
- 229960001967 tacrolimus Drugs 0.000 claims 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 3
- 229960002613 tamsulosin Drugs 0.000 claims 3
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims 3
- 229960001350 tofacitinib Drugs 0.000 claims 3
- 229960004751 varenicline Drugs 0.000 claims 3
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 claims 3
- 229940088594 vitamin Drugs 0.000 claims 3
- 229930003231 vitamin Natural products 0.000 claims 3
- 235000013343 vitamin Nutrition 0.000 claims 3
- 239000011782 vitamin Substances 0.000 claims 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims 3
- 230000008030 elimination Effects 0.000 claims 2
- 238000003379 elimination reaction Methods 0.000 claims 2
- 230000003449 preventive effect Effects 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 238000000465 moulding Methods 0.000 claims 1
- 239000002861 polymer material Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 229910052715 tantalum Inorganic materials 0.000 claims 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims 1
- 230000004962 physiological condition Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 3
- 125000005395 methacrylic acid group Chemical group 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FMPGQHYZYWZIKL-UHFFFAOYSA-N 6-amino-2-prop-2-enoylhexanoic acid Chemical compound NCCCCC(C(O)=O)C(=O)C=C FMPGQHYZYWZIKL-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- OGQLPJUHBHRUCA-UHFFFAOYSA-N 10-amino-2-(2-methylprop-2-enoyl)decanoic acid Chemical compound C(C(=C)C)(=O)C(C(=O)O)CCCCCCCCN OGQLPJUHBHRUCA-UHFFFAOYSA-N 0.000 description 1
- XPHNFTKWPVRJCM-UHFFFAOYSA-N 10-amino-2-prop-2-enoyldecanoic acid Chemical compound C(C=C)(=O)C(C(=O)O)CCCCCCCCN XPHNFTKWPVRJCM-UHFFFAOYSA-N 0.000 description 1
- BDQHVMXNDQTYGS-UHFFFAOYSA-N 11-amino-2-(2-methylprop-2-enoyl)undecanoic acid Chemical compound CC(=C)C(=O)C(C(O)=O)CCCCCCCCCN BDQHVMXNDQTYGS-UHFFFAOYSA-N 0.000 description 1
- XRZYQFQUJPVYQT-UHFFFAOYSA-N 11-amino-2-prop-2-enoylundecanoic acid Chemical compound NCCCCCCCCCC(C(O)=O)C(=O)C=C XRZYQFQUJPVYQT-UHFFFAOYSA-N 0.000 description 1
- MEVOABYJKISPQF-UHFFFAOYSA-N 12-amino-2-(2-methylprop-2-enoyl)dodecanoic acid Chemical compound C(C(=C)C)(=O)C(C(=O)O)CCCCCCCCCCN MEVOABYJKISPQF-UHFFFAOYSA-N 0.000 description 1
- OFFOKEDYYQHCFA-UHFFFAOYSA-N 12-amino-2-prop-2-enoyldodecanoic acid Chemical compound C(C=C)(=O)C(C(=O)O)CCCCCCCCCCN OFFOKEDYYQHCFA-UHFFFAOYSA-N 0.000 description 1
- CJPFRWHJXVQURI-UHFFFAOYSA-N 2-(3-aminopropyl)-3-oxopent-4-enoic acid Chemical group C(C=C)(=O)C(C(=O)O)CCCN CJPFRWHJXVQURI-UHFFFAOYSA-N 0.000 description 1
- DRSZVBVGXNKYMO-UHFFFAOYSA-N 2-(3-aminopropyl)-4-methyl-3-oxopent-4-enoic acid Chemical compound C(C(=C)C)(=O)C(C(=O)O)CCCN DRSZVBVGXNKYMO-UHFFFAOYSA-N 0.000 description 1
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- IQIAWUAJTBXDMZ-UHFFFAOYSA-N 6-amino-2-(2-methylprop-2-enoyl)hexanoic acid Chemical compound CC(=C)C(=O)C(C(O)=O)CCCCN IQIAWUAJTBXDMZ-UHFFFAOYSA-N 0.000 description 1
- WZCJCIWACGBZQR-UHFFFAOYSA-N 7-amino-2-(2-methylprop-2-enoyl)heptanoic acid Chemical compound C(C(=C)C)(=O)C(C(=O)O)CCCCCN WZCJCIWACGBZQR-UHFFFAOYSA-N 0.000 description 1
- YVYYDNBMGRPXHU-UHFFFAOYSA-N 7-amino-2-prop-2-enoylheptanoic acid Chemical compound C(C=C)(=O)C(C(=O)O)CCCCCN YVYYDNBMGRPXHU-UHFFFAOYSA-N 0.000 description 1
- HBZLHFQMFLJELN-UHFFFAOYSA-N 8-amino-2-(2-methylprop-2-enoyl)octanoic acid Chemical compound C(C(=C)C)(=O)C(C(=O)O)CCCCCCN HBZLHFQMFLJELN-UHFFFAOYSA-N 0.000 description 1
- UMTNFXRTMOOJGZ-UHFFFAOYSA-N 8-amino-2-prop-2-enoyloctanoic acid Chemical compound NCCCCCCC(C(O)=O)C(=O)C=C UMTNFXRTMOOJGZ-UHFFFAOYSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- NUXBFODAZOPYJU-UHFFFAOYSA-N 9-amino-2-(2-methylprop-2-enoyl)nonanoic acid Chemical compound C(C(=C)C)(=O)C(C(=O)O)CCCCCCCN NUXBFODAZOPYJU-UHFFFAOYSA-N 0.000 description 1
- XZTOZSFQTFZRGX-UHFFFAOYSA-N 9-amino-2-prop-2-enoylnonanoic acid Chemical compound C(C=C)(=O)C(C(=O)O)CCCCCCCN XZTOZSFQTFZRGX-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 229940124522 antiretrovirals Drugs 0.000 description 1
- 239000003903 antiretrovirus agent Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- LKFHUFAEFBRVQX-UHFFFAOYSA-N decanedioic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)CCCCCCCCC(O)=O LKFHUFAEFBRVQX-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- BFMKFCLXZSUVPI-UHFFFAOYSA-N ethyl but-3-enoate Chemical compound CCOC(=O)CC=C BFMKFCLXZSUVPI-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229940065514 poly(lactide) Drugs 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920001896 polybutyrate Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001299 polypropylene fumarate Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000012745 toughening agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462010992P | 2014-06-11 | 2014-06-11 | |
| US62/010,992 | 2014-06-11 | ||
| PCT/US2015/035423 WO2015191920A1 (en) | 2014-06-11 | 2015-06-11 | Residence structures and related methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020028439A Division JP2020097623A (ja) | 2014-06-11 | 2020-02-21 | 滞留構造体および関連方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524662A JP2017524662A (ja) | 2017-08-31 |
| JP2017524662A5 true JP2017524662A5 (enExample) | 2019-02-07 |
| JP6666858B2 JP6666858B2 (ja) | 2020-03-18 |
Family
ID=54834353
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016572445A Active JP6666858B2 (ja) | 2014-06-11 | 2015-06-11 | 滞留構造体および関連方法 |
| JP2017517216A Active JP6681390B2 (ja) | 2014-06-11 | 2015-06-11 | 腸溶性エラストマー |
| JP2016572439A Pending JP2017519003A (ja) | 2014-06-11 | 2015-06-11 | 自己集合滞留デバイスおよび関連方法 |
| JP2020000278A Pending JP2020056042A (ja) | 2014-06-11 | 2020-01-06 | 腸溶性エラストマー |
| JP2020028439A Withdrawn JP2020097623A (ja) | 2014-06-11 | 2020-02-21 | 滞留構造体および関連方法 |
| JP2020074561A Active JP7337746B2 (ja) | 2014-06-11 | 2020-04-20 | 自己集合滞留デバイスおよび関連方法 |
| JP2021202475A Active JP7405820B2 (ja) | 2014-06-11 | 2021-12-14 | 自己集合滞留デバイスおよび関連方法 |
| JP2022197093A Active JP7629898B2 (ja) | 2014-06-11 | 2022-12-09 | 滞留構造体および関連方法 |
| JP2024227227A Pending JP2025041821A (ja) | 2014-06-11 | 2024-12-24 | 滞留構造体および関連方法 |
Family Applications After (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517216A Active JP6681390B2 (ja) | 2014-06-11 | 2015-06-11 | 腸溶性エラストマー |
| JP2016572439A Pending JP2017519003A (ja) | 2014-06-11 | 2015-06-11 | 自己集合滞留デバイスおよび関連方法 |
| JP2020000278A Pending JP2020056042A (ja) | 2014-06-11 | 2020-01-06 | 腸溶性エラストマー |
| JP2020028439A Withdrawn JP2020097623A (ja) | 2014-06-11 | 2020-02-21 | 滞留構造体および関連方法 |
| JP2020074561A Active JP7337746B2 (ja) | 2014-06-11 | 2020-04-20 | 自己集合滞留デバイスおよび関連方法 |
| JP2021202475A Active JP7405820B2 (ja) | 2014-06-11 | 2021-12-14 | 自己集合滞留デバイスおよび関連方法 |
| JP2022197093A Active JP7629898B2 (ja) | 2014-06-11 | 2022-12-09 | 滞留構造体および関連方法 |
| JP2024227227A Pending JP2025041821A (ja) | 2014-06-11 | 2024-12-24 | 滞留構造体および関連方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (16) | US10413507B2 (enExample) |
| EP (5) | EP3155024B2 (enExample) |
| JP (9) | JP6666858B2 (enExample) |
| KR (2) | KR102471095B1 (enExample) |
| CN (4) | CN106573999A (enExample) |
| AU (6) | AU2015274456B2 (enExample) |
| BR (2) | BR122021018078B1 (enExample) |
| CA (3) | CA2951902C (enExample) |
| DK (2) | DK3725357T3 (enExample) |
| ES (2) | ES2832334T5 (enExample) |
| FI (2) | FI3155024T4 (enExample) |
| IL (1) | IL249435B (enExample) |
| MX (2) | MX2016016406A (enExample) |
| NZ (1) | NZ727659A (enExample) |
| PL (1) | PL3725357T3 (enExample) |
| RU (1) | RU2766335C2 (enExample) |
| SG (2) | SG10201912100SA (enExample) |
| WO (3) | WO2015191920A1 (enExample) |
| ZA (1) | ZA201608889B (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103948557A (zh) | 2014-04-08 | 2014-07-30 | 闻晓光 | 一种新型控释片 |
| CN106535878B (zh) | 2014-06-02 | 2022-11-01 | 科莱西奥生物科技有限公司 | 可张开的胃内滞留剂型 |
| JP6666858B2 (ja) | 2014-06-11 | 2020-03-18 | マサチューセッツ インスティテュート オブ テクノロジー | 滞留構造体および関連方法 |
| US20170266112A1 (en) | 2014-06-11 | 2017-09-21 | Massachusetts Institute Of Technology | Residence structures and related methods |
| AU2015319850B2 (en) | 2014-09-25 | 2019-09-26 | Bt Bidco, Inc. | Electromechanical pill device with localization capabilities |
| WO2016178971A1 (en) * | 2015-05-01 | 2016-11-10 | Massachusetts Institute Of Technology | Triggerable shape memory induction devices |
| EP3153137A1 (en) * | 2015-10-06 | 2017-04-12 | Li Galli B.V. | Vaginal drug delivery device and vaginal diagnostic device |
| US10939865B2 (en) * | 2015-10-06 | 2021-03-09 | Ligalli B.V. | Vaginal drug delivery device and vaginal diagnostic device |
| CN118975972A (zh) * | 2015-10-23 | 2024-11-19 | 林德拉治疗公司 | 用于治疗剂缓释的胃驻留系统及其使用方法 |
| EP3383365A1 (en) * | 2015-12-01 | 2018-10-10 | Clexio Biosciences Ltd. | Gastric retentive devices |
| BR112018011636B1 (pt) | 2015-12-08 | 2024-03-12 | Lyndra Therapeutics, Inc | Sistema de residência gástrico para liberação sustentada de um agente terapêutico |
| AU2016377694A1 (en) | 2015-12-22 | 2018-07-12 | Access Vascular, Inc. | High strength biomedical materials |
| US10470799B2 (en) * | 2016-04-21 | 2019-11-12 | Massachusetts Institute Of Technology | Origami robots, systems, and methods of treatment |
| CN119925721A (zh) * | 2016-05-27 | 2025-05-06 | 林德拉治疗公司 | 用于胃驻留系统的材料结构 |
| US20180070857A1 (en) | 2016-09-09 | 2018-03-15 | Progenity Inc. | Electromechanical ingestible device for delivery of a dispensable substance |
| CN110022861B (zh) * | 2016-09-30 | 2024-06-28 | 林德拉治疗公司 | 用于金刚烷类药物缓释的胃驻留系统 |
| EP3320898A1 (en) | 2016-11-11 | 2018-05-16 | ratiopharm GmbH | Dosage form comprising a carrier structure and method for manufacturing the dosage form |
| IL266377B2 (en) * | 2016-12-02 | 2023-10-01 | Clexio Biosciences Ltd | Gastric residence system |
| EP3551047A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| JP7049315B2 (ja) * | 2017-03-16 | 2022-04-06 | テルモ株式会社 | カテーテル組立体 |
| EP3900613B1 (en) | 2017-03-31 | 2023-12-27 | Biora Therapeutics, Inc. | Localization methods for an ingestible device |
| US11541015B2 (en) | 2017-05-17 | 2023-01-03 | Massachusetts Institute Of Technology | Self-righting systems, methods, and related components |
| IL301683B2 (en) | 2017-05-17 | 2025-02-01 | Massachusetts Inst Technology | Self-healing systems and related components and methods |
| AU2018279853B2 (en) * | 2017-06-09 | 2024-07-04 | Lyndra Therapeutics, Inc. | Gastric residence systems with release rate-modulating films |
| CA3067850A1 (en) | 2017-06-21 | 2018-12-27 | Access Vascular, Inc | High strength porous materials incorporating water soluble polymers |
| US11865145B2 (en) | 2017-08-07 | 2024-01-09 | Finch Therapeutics Holdings Llc | Compositions and methods for maintaining and restoring a healthy gut barrier |
| CN107773554A (zh) * | 2017-09-07 | 2018-03-09 | 华南农业大学 | 一种伊维菌素缓释微囊及其制备方法和应用 |
| ES3009743T3 (en) | 2017-09-20 | 2025-03-31 | Lyndra Therapeutics Inc | Encapsulation of gastric residence systems |
| WO2019083483A2 (en) * | 2017-10-11 | 2019-05-02 | Ege Universitesi | A vaginal implant |
| TWI837082B (zh) * | 2017-11-22 | 2024-04-01 | 美商萊恩卓治療公司 | 用於胃滯留系統之材料架構 |
| EP3716850A1 (en) * | 2017-11-28 | 2020-10-07 | Massachusetts Institute of Technology | Gastric resident electronics |
| WO2019111132A1 (en) | 2017-12-04 | 2019-06-13 | Clexio Biosciences Ltd. | Long acting gastric residence system |
| EP3793667A1 (en) | 2018-05-17 | 2021-03-24 | Massachusetts Institute of Technology | Systems for electrical stimulation |
| US20190365645A1 (en) * | 2018-05-31 | 2019-12-05 | Massachusetts Institute Of Technology | Drug delivery articles for gram-level dosing |
| WO2020036972A1 (en) * | 2018-08-15 | 2020-02-20 | Lyndra, Inc. | Systems for enteric delivery of therapeutic agents |
| US11648381B2 (en) | 2018-11-15 | 2023-05-16 | Massachusetts Institute Of Technology | Thermally controlled residence devices |
| WO2020102648A1 (en) | 2018-11-15 | 2020-05-22 | Massachusetts Institute Of Technology | Millineedle systems for esophageal drug delivery |
| WO2020101737A1 (en) * | 2018-11-15 | 2020-05-22 | Massachusetts Institute Of Technology | Actuating components and related methods |
| CN116726362A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| US12142158B2 (en) | 2018-12-03 | 2024-11-12 | Lyndra Therapeutics, Inc. | Stomach simulating device |
| US12194198B2 (en) | 2018-12-19 | 2025-01-14 | Access Vascular, Inc. | High strength porous materials for controlled release |
| US11771829B2 (en) | 2019-02-01 | 2023-10-03 | Massachusetts Institute Of Technology | Systems and methods for liquid injection |
| EP3941445A4 (en) | 2019-03-20 | 2023-08-02 | Lyndra Therapeutics, Inc. | CAPSULES AND CAPSULE COATINGS FOR GASOLINE DOSAGE FORMS |
| EP3941444B1 (en) * | 2019-03-20 | 2025-03-26 | Lyndra Therapeutics, Inc. | Coatings for gastric residence dosage forms |
| WO2020257017A1 (en) * | 2019-06-18 | 2020-12-24 | Progenity, Inc. | Ingestible device with component capable of residing in the gastrointestinal tract |
| CN110591125B (zh) * | 2019-07-31 | 2021-01-26 | 北京理工大学 | 一种可溶解的三维交联弹性体及其制备和处理方法 |
| CN119733161A (zh) * | 2019-10-01 | 2025-04-01 | 拉尼医疗有限公司 | 用于将制剂递送到管腔壁的自定尺寸装置 |
| AU2020379040A1 (en) * | 2019-11-08 | 2022-06-09 | Lyndra Therapeutics, Inc. | Gastric residence systems having a filament for improved gastric residence |
| EP4054545A4 (en) * | 2019-11-08 | 2024-02-14 | Lyndra Therapeutics, Inc. | GASTRIC STAY SYSTEMS FOR THE ADMINISTRATION OF ACTIVE AGENTS |
| WO2021092487A1 (en) * | 2019-11-08 | 2021-05-14 | Lyndra, Inc. | Polymeric linkers for a gastric residence system |
| WO2021092484A1 (en) * | 2019-11-08 | 2021-05-14 | Lyndra, Inc. | Gastric residence systems having arms with controlled stiffness for improved gastric residence |
| AU2020378437A1 (en) * | 2019-11-08 | 2022-06-02 | Lyndra Therapeutics, Inc. | Formulations for release-rate modulating films for gastric residence systems |
| US11541216B2 (en) | 2019-11-21 | 2023-01-03 | Massachusetts Institute Of Technology | Methods for manufacturing tissue interfacing components |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| WO2021178785A1 (en) * | 2020-03-06 | 2021-09-10 | Access Vascular, Inc. | Packaging for hydrated articles and related methods |
| US11253534B2 (en) | 2020-03-23 | 2022-02-22 | Sabine Hazan | Method of preventing COVID-19 infection |
| US11744866B2 (en) | 2020-03-18 | 2023-09-05 | Sabine Hazan | Methods of preventing and treating COVID-19 infection with probiotics |
| US11278520B2 (en) | 2020-03-31 | 2022-03-22 | Sabine Hazan | Method of preventing COVID-19 infection |
| WO2021231411A1 (en) * | 2020-05-12 | 2021-11-18 | Massachusetts Institute Of Technology | Gastroretentive articles for alcohol sensing |
| EP4171704A4 (en) | 2020-06-30 | 2024-10-23 | Access Vascular, Inc. | ARTICLES COMPRISING MARKINGS AND ASSOCIATED PROCESSES |
| JP2023536456A (ja) * | 2020-07-29 | 2023-08-25 | ザ・セカント・グループ・エルエルシー | 架橋ポリ（セバシン酸グリセロール）を含む構造を含む形状誘導型制御放出および保持 |
| EP4333823A4 (en) * | 2021-05-05 | 2025-04-09 | Lyndra Therapeutics, Inc. | Indwelling gastric sytems containing buprenorphine and naloxone |
| US20240245638A1 (en) | 2021-08-19 | 2024-07-25 | Clexio Biosciences Ltd. | Method of Treating Parkinson's Disease |
| EP4593929A2 (en) * | 2022-09-30 | 2025-08-06 | Lyndra Therapeutics, Inc. | Risperidone dosage regimens with gastric residence systems |
| WO2024081793A1 (en) | 2022-10-12 | 2024-04-18 | Massachusetts Institute Of Technology | Ingestible in vivo-assembling drug release formulations and methods |
| US20240398701A1 (en) * | 2023-06-02 | 2024-12-05 | Lyndra Therapeutics, Inc. | Manufacturing methods for gastric residence systems |
| WO2025090468A1 (en) * | 2023-10-24 | 2025-05-01 | Soane Pharma LLC | Orally ingestible delivery system |
| CN119971273A (zh) * | 2024-01-09 | 2025-05-13 | 厦门君德医药科技有限公司 | 一种胃滞留装置 |
| KR20250121713A (ko) * | 2024-02-05 | 2025-08-12 | 재단법인대구경북과학기술원 | 장내 생물학적 물질 다중 채취를 위한 채취 모듈 전달 캡슐 |
| WO2025199123A1 (en) * | 2024-03-19 | 2025-09-25 | Lyndra Therapeutics, Inc. | Flexible line configurations for gastric residence systems |
| CN120154807B (zh) * | 2024-03-22 | 2025-11-21 | 厦门君德医药科技有限公司 | 一种胃滞留装置 |
| WO2025222033A1 (en) * | 2024-04-18 | 2025-10-23 | The Regents Of The University Of California | Time-controlled payload release capsules |
Family Cites Families (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US415671A (en) * | 1889-11-19 | harris | ||
| US3154461A (en) * | 1960-03-07 | 1964-10-27 | Minnesota Mining & Mfg | Matte-finish polymeric film and method of forming the same |
| AU449029B2 (en) | 1969-08-28 | 1974-04-17 | Commonwealth Scientific And Industrial Research Organisation | Device for administration to ruminants |
| JPS5512411B2 (enExample) | 1974-03-12 | 1980-04-02 | ||
| US4199561A (en) * | 1979-02-26 | 1980-04-22 | The Dow Chemical Company | Coated nutrients and medicaments for veterinary use |
| US4451260A (en) | 1982-03-26 | 1984-05-29 | Minnesota Mining And Manufacturing Company | Sustained release oral medicinal delivery device |
| US4676507A (en) | 1985-05-06 | 1987-06-30 | Patterson Bruce D | Puzzles forming platonic solids |
| JPS6226215A (ja) * | 1985-05-10 | 1987-02-04 | メルク エンド カムパニ− インコ−ポレ−テツド | 一定に制御した時間内胃中に保持できる薬剤移送装置 |
| DE3680024D1 (de) * | 1985-05-10 | 1991-08-08 | Merck & Co Inc | Abgabesystem fuer arzneimittel, das waehrend einer kontrollierten zeitspanne im magen zurueckgehalten werden kann. |
| US4735804A (en) | 1985-05-10 | 1988-04-05 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
| US4767627A (en) * | 1985-05-29 | 1988-08-30 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
| US4758436A (en) | 1985-05-29 | 1988-07-19 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
| EP0253554A3 (en) * | 1986-07-15 | 1988-07-20 | Pfizer Inc. | Controlled release drug-containing fibers |
| IL87710A (en) | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
| EP0406315B1 (en) | 1988-03-24 | 1992-11-11 | Bukh Meditec A/S | Controlled release composition |
| US5002772A (en) | 1988-05-31 | 1991-03-26 | Pfizer Inc. | Gastric retention system for controlled drug release |
| NZ228382A (en) * | 1989-03-17 | 1992-08-26 | Carter Holt Harvey Plastic Pro | Drug administering coil-like device for insertion in body cavity of animal |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| JPH03163011A (ja) * | 1989-08-31 | 1991-07-15 | Yamanouchi Pharmaceut Co Ltd | 胃内滞留デバイス |
| US5047464A (en) | 1989-09-20 | 1991-09-10 | Merck & Co., Inc. | Bioerodible thermoset elastomers |
| US5369142A (en) * | 1993-01-15 | 1994-11-29 | The Ohio State University | Water soluble polymers containing amino acid residues for dental restoratives |
| WO1995003558A1 (en) * | 1993-07-19 | 1995-02-02 | Reflexite Corporation | Retroreflective structure |
| DE4406424A1 (de) | 1994-02-28 | 1995-08-31 | Bayer Ag | Expandierbare Arzneiformen |
| US6962579B2 (en) | 1995-03-23 | 2005-11-08 | Advanced Animal Technology Limited | Substance delivery device |
| DE69628344T2 (de) | 1995-03-23 | 2004-04-01 | Advanced Animal Technology Ltd. | Vorrichtung zur Verabreichung einer Substanz |
| TW354451B (en) | 1995-09-18 | 1999-03-11 | Ibm | Method of fabricating cross-linked biobased materials and structures fabricated therewith a method comprising the step of: forming the mixture of polymer and cross-linked agent |
| US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
| WO1997038969A1 (en) * | 1996-04-12 | 1997-10-23 | Japan Atomic Energy Research Institute | pH-SENSITIVE POLYMERS |
| GB9616267D0 (en) | 1996-08-02 | 1996-09-11 | Ranier Ltd | Balloon catheter |
| AU8699298A (en) | 1997-08-11 | 1999-03-01 | Alza Corporation | Prolonged release active agent dosage form adapted for gastric retention |
| DE19850309A1 (de) | 1998-10-30 | 2000-05-04 | Lohmann Therapie Syst Lts | Expandierbares gastroretensives Therapiesystem mit verlängerter Magenverweildauer |
| IL133196A0 (en) | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
| US20020022048A1 (en) | 2000-05-26 | 2002-02-21 | Bromberg Lev E. | Composite wafer for controlled drug delivery |
| US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| US8158143B2 (en) | 2000-07-14 | 2012-04-17 | Helmholtz-Zentrum Geesthacht Zentrum Fuer Material- Und Kuestenforschung Gmbh | Systems for releasing active ingredients, based on biodegradable or biocompatible polymers with a shape memory effect |
| US7803392B2 (en) | 2000-12-27 | 2010-09-28 | University Of Kentucky Research Foundation | pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules |
| US6627206B2 (en) | 2001-07-25 | 2003-09-30 | Greg A. Lloyd | Method and apparatus for treating obesity and for delivering time-released medicaments |
| US20040219186A1 (en) | 2001-08-16 | 2004-11-04 | Ayres James W. | Expandable gastric retention device |
| EP1416914A1 (en) | 2001-08-16 | 2004-05-12 | The State of Oregon acting by and through The State Board of Higher Education on behalf of Oregon State University | Expandable gastric retention device |
| CA2409552A1 (en) * | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
| KR100417163B1 (ko) | 2001-11-12 | 2004-02-05 | 한국과학기술연구원 | 마이크로 캡슐형 로봇 |
| US20050165136A1 (en) * | 2002-01-23 | 2005-07-28 | Uab Research Foundation | Glass-ionomer cements containing amino acids |
| AU2003234159A1 (en) * | 2002-04-22 | 2003-11-03 | Purdue Research Foundation | Hydrogels having enhanced elasticity and mechanical strength properties |
| DE10224352A1 (de) | 2002-06-01 | 2003-12-11 | Mueller Schulte Detlef | Thermosensitive Polymerträger mit veränderbarer physikalischer Struktur für die biochemische Analytik, Diagnostik und Therapie |
| GB0214013D0 (en) | 2002-06-18 | 2002-07-31 | Euro Celtique Sa | Pharmaceutical product |
| MY142179A (en) | 2002-07-25 | 2010-10-15 | Glaxo Group Ltd | Multicomponent pharmaceutical dosage form |
| CA2501345A1 (en) | 2002-10-11 | 2004-04-22 | Depomed Development, Ltd. | Gastro-retentive levodopa delivery form |
| EP1594475A1 (en) * | 2003-02-19 | 2005-11-16 | Mnemoscience GmbH | Self-expanding device for the gastrointestinal or urogenital area |
| JP4497833B2 (ja) * | 2003-04-21 | 2010-07-07 | 富士フイルム株式会社 | ポジ型平版印刷版原版 |
| US7662864B2 (en) * | 2003-06-04 | 2010-02-16 | Rutgers, The State University Of New Jersey | Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent |
| EP1633281A1 (de) | 2003-06-13 | 2006-03-15 | Mnemoscience GmbH | Stents |
| EP1638533A1 (en) | 2003-06-18 | 2006-03-29 | John Michael Newton | Controlled release devices with lumens |
| US8048169B2 (en) * | 2003-07-28 | 2011-11-01 | Baronova, Inc. | Pyloric valve obstructing devices and methods |
| US20090259236A2 (en) | 2003-07-28 | 2009-10-15 | Baronova, Inc. | Gastric retaining devices and methods |
| US7790141B2 (en) * | 2003-08-11 | 2010-09-07 | Pathak Holdings, Llc | Radio-opaque compounds, compositions containing same and methods of their synthesis and use |
| US6825308B1 (en) * | 2003-10-29 | 2004-11-30 | Council Of Scientific And Industrial Research | Copolymers and preparation thereof |
| AU2004296404A1 (en) | 2003-12-09 | 2005-06-23 | Spherics, Inc. | Bioadhesive polymers with catechol functionality |
| US20080089933A1 (en) | 2006-10-16 | 2008-04-17 | Amir Alon | Device and method for reducing calorie intake |
| WO2006033679A2 (en) * | 2004-05-25 | 2006-03-30 | Chimeracore, Inc. | Self-assembling nanoparticle drug delivery system |
| DE102004047076A1 (de) * | 2004-09-28 | 2006-04-06 | Zimmer Ag | Verfahren zur Herstellung von Polyestern |
| IL166183A0 (en) | 2005-01-06 | 2006-01-15 | Yissum Res Dev Co | Novel diagnostic and imaging techniques of the gi tract |
| US20060182788A1 (en) * | 2005-01-27 | 2006-08-17 | Parminder Singh | Hydrophilic biocompatible adhesive formulations and uses |
| ES2540929T3 (es) | 2005-02-01 | 2015-07-14 | Emisphere Technologies, Inc. | Sistema de administración de retención gástrica y liberación controlada |
| US7785291B2 (en) | 2005-03-01 | 2010-08-31 | Tulip Medical Ltd. | Bioerodible self-deployable intragastric implants |
| US7699863B2 (en) * | 2005-03-01 | 2010-04-20 | Tulip Medical Ltd. | Bioerodible self-deployable intragastric implants |
| JP2006323082A (ja) * | 2005-05-18 | 2006-11-30 | Canon Inc | 現像剤補給容器 |
| US8021384B2 (en) | 2005-07-26 | 2011-09-20 | Ram Weiss | Extending intrabody capsule |
| WO2007018138A1 (ja) | 2005-08-05 | 2007-02-15 | Shiga Prefecture | ポリマーブレンドを含んでなる液中物質移動材料 |
| US20070048383A1 (en) * | 2005-08-25 | 2007-03-01 | Helmus Michael N | Self-assembled endovascular structures |
| EP1957052A2 (en) | 2005-10-25 | 2008-08-20 | Pharmascience Inc. | A gastric retention drug delivery system |
| EP1945189A4 (en) * | 2005-11-03 | 2012-08-15 | Sun Pharmaceutical Ind Ltd | CONTROLLED RELEASE COATED TABLETS CHARACTERIZED BY PROLONGED GASTRIC RETENTION |
| US7674396B2 (en) | 2005-11-08 | 2010-03-09 | Plensat Llc | Method and system for treatment of eating disorders |
| US8298574B2 (en) | 2006-01-18 | 2012-10-30 | Intec Pharma Ltd. | Method and apparatus for forming delivery devices for oral intake of an agent |
| CA2642479C (en) | 2006-02-15 | 2014-08-19 | Intec Pharma Ltd. | A gastro-retentive system for the delivery of macromolecules |
| WO2007106415A2 (en) * | 2006-03-10 | 2007-09-20 | Massachusetts Institute Of Technology | Triggered self-assembly conjugates and nanosystems |
| US7691151B2 (en) | 2006-03-31 | 2010-04-06 | Spiration, Inc. | Articulable Anchor |
| US20070264307A1 (en) | 2006-05-15 | 2007-11-15 | Medtronic Vascular, Inc. | Biodegradable Modified Caprolactone Polymers for Fabricating and Coating Medical Devices |
| EP1886665A1 (en) | 2006-08-01 | 2008-02-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Gastro retentive delivery system |
| BRPI0716481A2 (pt) | 2006-09-04 | 2014-03-18 | Panacea Biotec Ltd | Tecnologia de liberação flutuante programável |
| US20080075766A1 (en) | 2006-09-25 | 2008-03-27 | Shun-Por Li | Multi-core dosage form having transparent outer coating |
| AU2007338631A1 (en) * | 2006-12-22 | 2008-07-03 | Combinatorx, Incorporated | Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
| US8507778B2 (en) | 2007-03-13 | 2013-08-13 | Arthur J. Olson | Self-assembled polyhedra |
| WO2008111077A2 (en) * | 2007-03-13 | 2008-09-18 | Technion Research & Development Foundation Ltd. | Self-assembled polyhedral multimeric chemical structures |
| US20080249156A1 (en) * | 2007-04-09 | 2008-10-09 | Palepu Nageswara R | Combinations of statins and anti-obesity agent and glitazones |
| CA2687979C (en) | 2007-05-25 | 2017-07-04 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of risperidone compounds |
| WO2008148083A1 (en) * | 2007-05-25 | 2008-12-04 | Gorham Enterprises Llc | Bariatric magnetic apparatus and method of manufacturing thereof |
| US8038659B2 (en) * | 2007-10-17 | 2011-10-18 | The Invention Science Fund I, Llc | Disintegrating digestive tract interaction system |
| US8303573B2 (en) * | 2007-10-17 | 2012-11-06 | The Invention Science Fund I, Llc | Medical or veterinary digestive tract utilization systems and methods |
| AU2009223061B2 (en) | 2008-03-11 | 2014-10-09 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| US20130273135A1 (en) | 2008-03-25 | 2013-10-17 | University Of Utah Research Foundation | Controlled Release Combination Biomaterials |
| ES2606395T3 (es) | 2008-04-18 | 2017-03-23 | Intec Pharma Ltd. | Administración de fármacos gastrorretentivos para carbidopa/levodopa |
| US9066877B2 (en) * | 2008-04-28 | 2015-06-30 | Eat Little Inc. | Bezoar-forming units for weight control |
| US20100256342A1 (en) * | 2008-08-12 | 2010-10-07 | Francis Raymond Salemme | Protein nodes for controlled nanoscale assembly |
| JP2012500230A (ja) | 2008-08-18 | 2012-01-05 | 北京天衡▲薬▼物研究院 | 胃内滞留薬物放出システム及びその製造方法と使用 |
| PL2349222T3 (pl) | 2008-09-10 | 2017-08-31 | Sandoz Ag | Kapsułka z rozpuszczalnym elementem blokującym |
| US20110268666A1 (en) | 2008-09-29 | 2011-11-03 | Yissum Research Development Company of the Research University of Jerusalem, Ltd. | Novel gastroretentive delivery system |
| PL2378883T3 (pl) | 2008-12-04 | 2016-06-30 | Intec Pharma Ltd | SYSTEM DOSTARCZANIA LEKU ZATRZYMYWANEGO W ŻOŁĄDKU dLA ZALEPLONU |
| CA2746989A1 (en) * | 2008-12-27 | 2010-07-01 | Chandra S. Duggirala | Devices for treating obesity and methods of using those devices |
| CN102414116B (zh) * | 2009-02-26 | 2015-01-21 | 加利福尼亚大学董事会 | 用于制备尺寸可控的纳米颗粒的超分子方法 |
| US8414559B2 (en) | 2009-05-07 | 2013-04-09 | Rainbow Medical Ltd. | Gastroretentive duodenal pill |
| DE102009028076A1 (de) | 2009-07-29 | 2011-02-03 | Evonik Röhm Gmbh | Beschichtungsmittel zum Tauchbeschichten von Kapselhälften |
| US20110052497A1 (en) * | 2009-08-27 | 2011-03-03 | Taris Biomedical, Inc. | Minimally Invasive Systems and Methods for In Vivo Testing of Materials |
| US20110052700A1 (en) | 2009-08-31 | 2011-03-03 | Depomed, Inc. | Gastric retentive pharmaceutical compositions for immediate and extended release of levosulpiride |
| WO2011032087A2 (en) | 2009-09-11 | 2011-03-17 | Replication Medical Inc. | Swellable polymeric device for dietary regulation |
| US20120321706A1 (en) | 2009-10-19 | 2012-12-20 | Intec Pharma Ltd. | Novel gastroretentive dosage forms of poorly soluble drugs |
| US9421169B2 (en) | 2009-11-20 | 2016-08-23 | Covidien Lp | Oral dosage forms for delivery of therapeutic agents |
| CN101711752B (zh) | 2009-11-26 | 2011-09-21 | 中国科学院上海药物研究所 | 一种苯并异噁唑类衍生物的控释制剂及其制备方法 |
| AU2010336330B2 (en) * | 2009-12-24 | 2016-04-28 | Rani Therapeutics, Llc | Swallowable drug delivery device and methods of drug delivery |
| JP2013527157A (ja) * | 2010-04-15 | 2013-06-27 | ワシントン・ユニバーシティ | プロドラッグ組成物、プロドラッグナノ粒子およびその使用方法 |
| WO2011139796A2 (en) * | 2010-04-27 | 2011-11-10 | The Johns Hopkins University | Self-folding sub-centimeter structures |
| BRPI1002601E2 (pt) * | 2010-06-01 | 2020-06-30 | Embrapa Pesquisa Agropecuaria | composição nanoestruturada de uso veterinário para administração de fármacos |
| US20120165793A1 (en) | 2010-12-22 | 2012-06-28 | Ethicon Endo-Surgery, Inc. | Pill Catchers |
| US20120165794A1 (en) | 2010-12-22 | 2012-06-28 | Ethicon Endo-Surgery, Inc. | Pill Catchers |
| US20120165792A1 (en) | 2010-12-22 | 2012-06-28 | Ethicon Endo-Surgery, Inc. | Pill Catchers |
| WO2012106714A1 (en) | 2011-02-04 | 2012-08-09 | Taris Biomedical, Inc. | Implantable device for controlled release of low solubility drug |
| JP2014533975A (ja) * | 2011-09-26 | 2014-12-18 | ノースイースタン・ユニバーシティ | カスタマイズ可能な埋め込みセンサ |
| US8835507B2 (en) | 2012-02-21 | 2014-09-16 | Vymed Corporation | Adamantane derivatives possessing anti-viral and anti-microbial activity |
| US8979887B2 (en) | 2012-02-24 | 2015-03-17 | Elwha Llc | Devices, systems, and methods to control stomach volume |
| AU2013290875A1 (en) | 2012-07-16 | 2015-02-05 | APET Holding B.V. | Gastro-retentive drug delivery system |
| US9307966B2 (en) | 2012-08-15 | 2016-04-12 | St. Jude Medical Puerto Rico Llc | Vascular closure device anchor |
| IN2015DN01023A (enExample) | 2012-08-16 | 2015-06-26 | Teva Pharma | |
| US8746339B2 (en) * | 2012-09-27 | 2014-06-10 | Halliburton Energy Services, Inc. | Triggerable lost circulation material and method of use |
| US10441760B2 (en) | 2013-03-01 | 2019-10-15 | The Johns Hopkins University | Self-actuating chemomechanical devices for delivery and extended release of therapeutic agents in the gastrointestinal tract |
| CN103654903A (zh) * | 2013-11-27 | 2014-03-26 | 西安交通大学 | 一种用于人体消化道吻合的磁性可降解装置 |
| CA2932574C (en) | 2013-12-05 | 2023-03-07 | Tulip Medical Ltd. | Retentive devices and systems for in-situ release of pharmaceutical active agents |
| US20170051099A1 (en) | 2014-04-29 | 2017-02-23 | The Brigham And Women's Hospital, Inc. | Polymeric materials for bio-applications |
| CN106456550A (zh) | 2014-05-26 | 2017-02-22 | 格吕伦塔尔有限公司 | 避免乙醇剂量倾泻的多颗粒 |
| CN106535878B (zh) | 2014-06-02 | 2022-11-01 | 科莱西奥生物科技有限公司 | 可张开的胃内滞留剂型 |
| US20170266112A1 (en) | 2014-06-11 | 2017-09-21 | Massachusetts Institute Of Technology | Residence structures and related methods |
| JP6666858B2 (ja) | 2014-06-11 | 2020-03-18 | マサチューセッツ インスティテュート オブ テクノロジー | 滞留構造体および関連方法 |
| WO2016178971A1 (en) | 2015-05-01 | 2016-11-10 | Massachusetts Institute Of Technology | Triggerable shape memory induction devices |
| CN118975972A (zh) | 2015-10-23 | 2024-11-19 | 林德拉治疗公司 | 用于治疗剂缓释的胃驻留系统及其使用方法 |
| BR112018011636B1 (pt) | 2015-12-08 | 2024-03-12 | Lyndra Therapeutics, Inc | Sistema de residência gástrico para liberação sustentada de um agente terapêutico |
| CN119925721A (zh) | 2016-05-27 | 2025-05-06 | 林德拉治疗公司 | 用于胃驻留系统的材料结构 |
| CN110022861B (zh) | 2016-09-30 | 2024-06-28 | 林德拉治疗公司 | 用于金刚烷类药物缓释的胃驻留系统 |
| EP4281049A4 (en) * | 2021-01-19 | 2025-04-23 | Lyndra Therapeutics, Inc. | GASTRIC RESIDENCE SYSTEMS FOR RISPERIDONE DELIVERY |
-
2015
- 2015-06-11 JP JP2016572445A patent/JP6666858B2/ja active Active
- 2015-06-11 EP EP15806017.8A patent/EP3155024B2/en active Active
- 2015-06-11 JP JP2017517216A patent/JP6681390B2/ja active Active
- 2015-06-11 FI FIEP15806017.8T patent/FI3155024T4/fi active
- 2015-06-11 RU RU2017100273A patent/RU2766335C2/ru active
- 2015-06-11 CA CA2951902A patent/CA2951902C/en active Active
- 2015-06-11 EP EP24211120.1A patent/EP4516322A3/en active Pending
- 2015-06-11 MX MX2016016406A patent/MX2016016406A/es unknown
- 2015-06-11 BR BR122021018078-4A patent/BR122021018078B1/pt active IP Right Grant
- 2015-06-11 AU AU2015274456A patent/AU2015274456B2/en active Active
- 2015-06-11 WO PCT/US2015/035423 patent/WO2015191920A1/en not_active Ceased
- 2015-06-11 BR BR112016028957-9A patent/BR112016028957B1/pt active IP Right Grant
- 2015-06-11 EP EP20160645.6A patent/EP3725357B1/en active Active
- 2015-06-11 CN CN201580038008.XA patent/CN106573999A/zh active Pending
- 2015-06-11 FI FIEP20160645.6T patent/FI3725357T3/fi active
- 2015-06-11 JP JP2016572439A patent/JP2017519003A/ja active Pending
- 2015-06-11 ES ES15806017T patent/ES2832334T5/es active Active
- 2015-06-11 KR KR1020177000698A patent/KR102471095B1/ko active Active
- 2015-06-11 CN CN202211697823.5A patent/CN116370644A/zh active Pending
- 2015-06-11 NZ NZ727659A patent/NZ727659A/en unknown
- 2015-06-11 WO PCT/US2015/035429 patent/WO2015191925A1/en not_active Ceased
- 2015-06-11 DK DK20160645.6T patent/DK3725357T3/da active
- 2015-06-11 AU AU2015274451A patent/AU2015274451C1/en active Active
- 2015-06-11 US US15/317,601 patent/US10413507B2/en active Active
- 2015-06-11 CN CN201580038072.8A patent/CN106573015B/zh active Active
- 2015-06-11 CN CN201580038062.4A patent/CN106714893B/zh active Active
- 2015-06-11 EP EP15806483.2A patent/EP3154553B1/en active Active
- 2015-06-11 SG SG10201912100SA patent/SG10201912100SA/en unknown
- 2015-06-11 WO PCT/US2015/035425 patent/WO2015191922A1/en not_active Ceased
- 2015-06-11 US US15/317,566 patent/US10182985B2/en active Active
- 2015-06-11 CA CA2951909A patent/CA2951909C/en active Active
- 2015-06-11 US US15/317,628 patent/US10849853B2/en active Active
- 2015-06-11 AU AU2015274453A patent/AU2015274453A1/en not_active Abandoned
- 2015-06-11 DK DK15806017.8T patent/DK3155024T4/da active
- 2015-06-11 EP EP15805932.9A patent/EP3154622B1/en active Active
- 2015-06-11 KR KR1020227040906A patent/KR102704895B1/ko active Active
- 2015-06-11 ES ES20160645T patent/ES3001020T3/es active Active
- 2015-06-11 PL PL20160645.6T patent/PL3725357T3/pl unknown
- 2015-06-11 CA CA2951884A patent/CA2951884A1/en active Pending
- 2015-06-11 SG SG11201610246PA patent/SG11201610246PA/en unknown
-
2016
- 2016-12-07 IL IL249435A patent/IL249435B/en active IP Right Grant
- 2016-12-09 MX MX2023005223A patent/MX2023005223A/es unknown
- 2016-12-22 ZA ZA2016/08889A patent/ZA201608889B/en unknown
-
2018
- 2018-11-01 US US16/177,670 patent/US10532027B2/en active Active
- 2018-11-01 US US16/177,687 patent/US20190070108A1/en not_active Abandoned
- 2018-11-01 US US16/177,704 patent/US10610482B2/en active Active
-
2019
- 2019-02-15 US US16/277,516 patent/US10517819B2/en active Active
- 2019-04-09 US US16/379,727 patent/US10517820B2/en active Active
- 2019-07-31 US US16/528,197 patent/US11083690B2/en active Active
- 2019-09-19 AU AU2019232862A patent/AU2019232862A1/en not_active Abandoned
- 2019-11-22 US US16/693,149 patent/US10716752B2/en active Active
- 2019-11-22 US US16/693,121 patent/US10716751B2/en active Active
-
2020
- 2020-01-06 JP JP2020000278A patent/JP2020056042A/ja active Pending
- 2020-01-17 AU AU2020200346A patent/AU2020200346B2/en active Active
- 2020-02-21 JP JP2020028439A patent/JP2020097623A/ja not_active Withdrawn
- 2020-04-20 JP JP2020074561A patent/JP7337746B2/ja active Active
- 2020-06-11 US US16/899,447 patent/US11246829B2/en active Active
- 2020-12-18 US US17/126,786 patent/US11077056B2/en active Active
- 2020-12-18 US US17/126,835 patent/US11389399B2/en active Active
-
2021
- 2021-02-12 US US17/174,458 patent/US11357723B2/en active Active
- 2021-05-14 AU AU2021203086A patent/AU2021203086B2/en active Active
- 2021-12-14 JP JP2021202475A patent/JP7405820B2/ja active Active
-
2022
- 2022-06-09 US US17/836,972 patent/US20230039421A1/en active Pending
- 2022-12-09 JP JP2022197093A patent/JP7629898B2/ja active Active
-
2024
- 2024-12-24 JP JP2024227227A patent/JP2025041821A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524662A5 (enExample) | ||
| JP7629898B2 (ja) | 滞留構造体および関連方法 | |
| JP7550201B2 (ja) | 自己復元システムならびに関連構成要素および方法 | |
| JP2025041821A5 (enExample) | ||
| US20210361919A1 (en) | Quick release capsules | |
| Singh et al. | Pulsatile drug delivery system: an approach of medication according to circadian rhythm | |
| CN101378736A (zh) | 用于口服给药的多微粒药物剂型 | |
| Ibrahim et al. | Gastro-retentive oral drug delivery systems: A promising approach for narrow absorption window drugs | |
| JP2010502642A (ja) | バルサルタンのための持続放出性胃滞留型経口薬物送達システム | |
| JP2021509076A (ja) | 胃滞在電子機器 | |
| CN101287443A (zh) | pH控制的脉冲释放系统、其制备方法和用途 | |
| US20220001159A1 (en) | Actuating components and related methods | |
| Chordiya et al. | Technologies, optimization and analytical parameters in gastroretentive drug delivery systems | |
| US12171879B2 (en) | Articles and methods for administration of therapeutic agents | |
| Fish et al. | Drug delivery to the colon | |
| WO2020257017A1 (en) | Ingestible device with component capable of residing in the gastrointestinal tract | |
| Yadav et al. | Recent advances in colon specific drug delivery system | |
| WO2025043030A1 (en) | Gastroretentive dosage form for prolonged drug delivery | |
| Singh et al. | Gastroretentive Delivery | |
| JPWO2007069358A1 (ja) | 新規胃内滞留製剤 | |
| Doshi et al. | A Systemic Review on Pulsatile Drug Delivery System with Colon Specificity | |
| Reshma | Formulation and Evaluation of Olmesartan Medoxomil Pulsatile Drug Delivery System |